A STROBE-compliant case–control study
Effects of cumulative doses of topical atropine on intraocular pressure and myopia progression

Teng-Chieh Yu, MDa, Tzu-En Wu, MD, MSa,b,c, *, Yuan-Shen Wang, MDa, Shen-Fu Cheng, MDa, Shiow-Wen Liou, MD, PhDa,d

Abstract
Topical atropine has become a mainstream treatment of myopia throughout East and Southeast Asia, but it is uncertain whether long-term topical atropine therapy induces intraocular pressure (IOP) elevation and subsequent development of glaucoma. We then prospectively examined the effects of long-term atropine treatment on IOP.

Our case series collected 186 myopic children who were younger than 16 years of age. Complete ocular examination data, IOP and refractive status measurements beginning in 2008 were collected for all participants. Participants were divided into two groups: 121 children who received atropine therapy at various concentrations were classified as the treated group, whereas 65 children who did not receive atropine therapy were classified as the untreated (reference) group. In the treated group, clinicians prescribed different concentrations of atropine eye drops according to their discretion with regard to the severity of myopia on each visit of the patient. We then calculated the cumulative dose of atropine therapy from 2008 to the patients’ last follow-up in 2009. Furthermore, the treated group was then further divided into low- and high-refractive-error groups of nearly equal size for further analysis.

There were no significant differences for the baseline refractive errors and IOPs between the treated and untreated groups. Both the low- and high-cumulative atropine dosage subgroups showed significantly lower myopic progression than the untreated group, but there was no significant difference between the two subgroups in terms of different cumulative dosages. All groups, including the untreated group, showed an increase of mean IOP at the last follow-up, but both low- and high-cumulative atropine dosage subgroups experienced a smaller increase of IOP. The mean IOP of all atropine-treated groups showed no significant increase in either low- or high-refractive-error eyes.

This study revealed that topical atropine eye drops do not induce ocular hypertension and are effective for slowing the progression of myopia. The treatment effects are not correlated with the cumulative atropine dosages.

Abbreviations: ANOVA = analysis of variance, D = diopters, IOP = intraocular pressure, OCT = optical coherence tomography, SE = spherical equivalent.

Keywords: atropine, intraocular pressure, myopia

Editor: Cigdem Sayil.
The authors have no conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

* Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. School of Medicine, Fu Jen Catholic University, New Taipei City. b Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. c Department of Ophthalmology, School of Medicine, National Taiwan University, Taipei, Taiwan.

* Correspondence: Tzu-En Wu, Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen Chang Road, Shih Lin District, Taipei City 111, Taiwan (e-mail: m001055@ms.skh.org.tw).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Yu TC, Wu TE, Wang YS, Cheng SF, Liou SW. A STROBE-compliant case–control study: Effects of cumulative doses of topical atropine on intraocular pressure and myopia progression. Medicine 2020;99:48 (e22745).
Received: 27 August 2019 / Received in final form: 25 April 2020 / Accepted: 14 September 2020 http://dx.doi.org/10.1097/MD.0000000000022745

1. Introduction

Myopia is one of the most common ocular disorders, and its rapidly increasing prevalence is becoming an important public health problem worldwide. The prevalence of myopia in young adults in several Asian countries such as Taiwan, Hong Kong, and Singapore is 60% to 80%, higher than that in the United States and Europe (20%–60%).[1–5] Myopia-related complications include macular degeneration, retinal detachment, glaucoma, and cataracts.[4,6–8] Due to these potentially blinding complications, the World Health Organization proposed the Strategic Plan for Vision 2020 to eliminate avoidable blindness with refractive error, including myopia.[9]

Atropine, a non-selective muscarinic receptor antagonist, has been successfully used to prevent the progression of myopia in Asian children.[10–16] In fact, topical atropine has become a mainstream treatment of myopia throughout East and Southeast Asia.[11,17–20] After conducting an evidence-based review, Saw et al.[17] recommended that the evidence rating of atropine therapy be set at B-I, where “B” means a moderately important recommendation for clinical outcome and “I” means that there is strong evidence supporting the recommendation. However, the routine use of atropine in all myopic children is not recommended due to the lack of long-term studies and the possible side
One of the potential complications of this treatment is an increase in intraocular pressure (IOP). The antimuscarinic effects of atropine can paralyze the ciliary muscle and thus may increase the drainage resistance of aqueous humor through the trabecular meshwork. Systemic atropine was found to increase IOP by more than 6 mm Hg in 8% of normal adults. Atropine and other anticholinergic agents are, therefore, contraindicated for glaucoma patients. The risk factors of glaucoma with atropine are short hyperopic eyes, narrow angles, and occlusion of aqueous outflow. In myopic children, it is unclear whether topical atropine therapy induces IOP elevation and subsequent development of glaucoma. The safety of long-term atropine treatment has also been largely overlooked. In 2012, we conducted the first cross-sectional study to evaluate IOP after 3 years of treatment with varying cumulative dosages of atropine in school-aged myopic children, and found neither the cumulative dose nor the duration of atropine therapy was statistically associated with the risk of IOP elevation. Considering that there might be some potential bias due to the cross-sectional and retrospective nature of the study, we decided to conduct this prospective case series study to further evaluate the safety of varying cumulative dosages of atropine.

### 2. Patients and methods

#### 2.1. Patients

In 2008, we conducted this prospective, interventional, longitudinal, and non-randomized study of 190 children at Shin-Kong Wu Ho-Su Memorial (SK) Hospital’s Department of Ophthalmology in Taipei, Taiwan, R.O.C. This study was primarily designed to evaluate whether topical atropine can increase IOP in myopic children with a refractive error of myopic spherical equivalent (SE) > -0.25 diopters (D) in at least one eye. All patients were recruited and followed at the clinic of Dr Tzu-En Wu. The research adhered to the tenets of the Declaration of Helsinki. Informed consent and Institutional Review Board approval at the SK Hospital (98E-005) were both obtained. The study (treated) group consisted of 122 myopic children (60 boys and 62 girls) younger than 16 years old who were treated with topical atropine. The exclusion criteria included:

1. having a congenital eye disorder;
2. any disease influencing the cornea, lens, retina, or optic nerve; and
3. the current use of other cycloplegic agents, steroids, or antiglaucoma medications.

On each visit, clinicians prescribed different concentrations of atropine eye drops, such as 1%, 0.5%, 0.25%, and 0.1% (Oasis Chemical Industries, Dombivli, India) according to their discretion with regard to the severity of myopia in the patient. The control (untreated) group consisted of 68 myopic children (40 boys and 28 girls) who did not receive atropine to control myopia. The primary outcome measures were to evaluate the effects on IOP and refractive status under various cumulative dosages of atropine in myopic children. The secondary aim was to assess the above outcome measures in different refractive statuses. The data regarding SE, IOP, and concentrations of atropine treatment were collected for the period between January 1, 2008 and December 31, 2009. We had excluded one child without final refractive error measurements, and three children without final IOP measurements. Figure 1 shows the algorithm of case identification and a total of 186 children (372 eyes) were eligible for final analysis.

#### 2.2. Ocular examinations

The standard ocular examinations for myopic children at the SK Hospital were

1. a slit lamp biomicroscopy for anterior segment and lens,
2. assessment of refractive errors; and
3. fundoscopic examinations.

All examination results revealed normal status except for the refractive errors before the study. We first assessed refractive errors by using a Canon RK5 autorefractor/autokeratometer (Canon, Ota, Japan). When the results revealed the probable presence of myopia, a cycloplegic procedure was used with three drops of 1% Cyclogyl (cyclopentolate) (Alcon-Couvreur, Puurs, Belgium) given at 10-min intervals. Cycloplegic autorefration was taken at least 30 min after instillation of the third drop of cyclopentolate, and converted to SE refraction for analysis. Cycloplegic visual acuity with correction was measured using a projected Snellen chart at a distance of 6 m.

All IOP measurements were obtained before cyclopentolate instillation. We used an Xpert NCT plus (Reichert Technologies, Buffalo, NY) to perform pneumatic tonometry without topical anesthesia on both eyes in conscious children, with the right eye first. Every child was in seated position with eyes in the primary position during IOP measurement. No lid speculum was used. Before measurement, the alignment spot was centered and not obscured by the eyelashes or eyelids. Each patient received three measurements and the average of those measurements was the

---

**Figure 1.** The algorithm of case identification. Initially, data were collected for 190 children <16 years old and who had refractive error of myopic spherical equivalent > -0.25 diopters in at least one eye. We excluded one myopic child without final refractive error, and three children without final intraocular pressure. A total of 186 children (372 eyes) were eligible for final analysis and their medical records were reviewed for the period between January 1, 2008 and December 31, 2009.
final IOP. The IOP was measured between 9 AM and 1 PM. If patients underwent all the above procedures, IOP was recorded and the day of IOP measurement in 2008 was defined as the recruitment date.

2.3. Measurement of atropine exposure and other characteristics

The medical records from a total of 186 myopic children (98 boys and 88 girls, aged 9.0 ± 2.3 years) who were eligible for final analysis (Fig. 1) were collected for refractive status, medical history, ocular disease, and the duration and dose of atropine treatment. One hundred twenty-one children who were scheduled for atropine therapy on the recruitment date were classified as the treated group, while the other 65 children who were not recommended atropine therapy were classified as the untreated group. The duration of atropine exposure was calculated from the first date of atropine prescription in 2008 to the date of the last follow-up in 2009. On each visit, clinicians prescribed different concentrations of atropine eye drop, such as 1%, 0.5%, 0.25%, and 0.1% (Oasis Chemical Industries) according to their discretion with regard to the severity of myopia in the children. The exact dosage of each bottle for atropine was 50, 25, 12.5, and 5 mg, respectively. The dosage of atropine prescribed at each visit was assessed by multiplying the number of prescribed bottles and the dosage of atropine in each bottle; we used this method to calculate the prescribed dosage of atropine for each outpatient visit. The concentration we used was the original concentration from the pharmacological corporation. No dilution or condensation occurred at any point during the study and no patient shared the same bottle of atropine. Data collection was halted if a patient experienced a severe allergic reaction and proper management was subsequently arranged by medical professionals. No patients in the untreated group received any placebo eye drops in this study.

2.4. Statistical analyses

All statistical analyses were conducted using SPSS software version 25 (IBM, Armonk, NY). Two sample independent t tests were used to compare the subject characteristics, including age, SE, and IOP, between the atropine-treated and untreated groups. The gender among groups was evaluated using the Chi-square test. An analysis of variance (ANOVA) was conducted to evaluate the effects of cumulative atropine dosages, which were divided into tertiles. In comparing the IOP and refractive errors among the three groups, we analyzed variance first. If the variances among the three groups were homogeneous, we used ANOVA for analysis and added Fisher’s Least Significant Difference test for post hoc analysis of equally sized groups. The Scheffe test was used for post hoc analysis of unequally sized groups. If the variances among the three groups were heterogeneous, we used Welch’s test for analysis and added the Games-Howell test for post hoc analysis. Confidence intervals of 95% were regarded as a comparison for mean values and P < .05 was considered statistically significant for the paired-t, Chi-square, ANOVA, and Welch’s tests.

3. Results

3.1. Comparison of IOP, refractive status, and atropine therapy

A total of 186 myopic children aged younger than 16 years were enrolled in this study. Table 1 summarizes the details of refractive status for both eyes, IOP measurements, and the cumulative dosages of atropine therapy. Patients in the treated group were significantly younger and made more outpatient visits than the untreated group (P < .05 in both parameters). There were no significant differences in refractive errors or IOPs between treated and untreated groups (Table 1). The mean examination follow-up period was 10.6 ± 4.0 months, and the mean cumulative atropine dosage was 36.04 ± 49.66 mg in these 186 children. No atropine-treated patient had experienced a severe allergic reaction or an acute angle-closure glaucoma attack.

3.2. Distribution of demographic and clinical characteristics by tertiles of cumulative dose of atropine therapy in 186 myopic children

We further compared the demographic and clinical characteristics between subgroups with different cumulative dosages of atropine therapy stratified by tertiles (Table 2). Both low- and high-cumulative atropine dosage subgroups showed significantly lower myopic progression, but there was no significant difference between the two subgroups with different cumulative dosages. All groups, including the untreated group, showed an increase of mean IOP at the last follow-ups, but both the low- and high-

| Variables | Atropine-treated group (N = 121) | Non-treated group (N = 65) | P |
|-----------|----------------------------------|--------------------------|---|
| Age (year) | 8.6 ± 2.3 | 9.6 ± 2.3 | .008 |
| OD | 1.5 ± 1.4 | -1.3 ± 1.4 | .238 |
| C (D) | -0.6 ± 0.9 | -0.6 ± 0.9 | .810 |
| SE (D) | -1.8 ± 1.5 | -1.6 ± 1.6 | .267 |
| IOP (mm Hg) | 14.2 ± 2.8 | 14.5 ± 2.5 | .463 |
| OS | -1.5 ± 1.7 | -1.1 ± 1.2 | .107 |
| C (D) | -0.6 ± 1.0 | -0.6 ± 0.9 | .713 |
| SE (D) | -1.8 ± 2.0 | -1.4 ± 1.5 | .138 |
| IOP (mm Hg) | 14.4 ± 2.8 | 14.3 ± 2.8 | .954 |
| Number of outpatient visits | 61 ± 2.6 | 46 ± 3.1 | .001 |
| Cumulative dose of atropine (mg) | 55.4 ± 52.2 | 0.0 ± 0.0 | <.001 |

C = cylinder refraction, D = diopeter, IOP = intraocular pressure, OD = ocarius dexter, OS = ocarius sinister, S = spherical refraction, SE = spherical equivalent.
cumulative atropine dosage subgroups experienced a smaller IOP increase.

### 3.3. The effects of various cumulative atropine dose in eyes with different myopic SE

To evaluate the effects of various cumulative atropine in eyes with different myopic SEs, all 242 eyes of the 121 atropine-treated children in our study were further divided into low- and high-refractive-error groups with nearly equal size, at a SE cutoff point of −1.50 D. There were 44.4% of the eyes having a myopic SE of −1.5 D or greater (47.3% in the right eyes, and 41.4% in the left eyes). The mean SE of all subgroups in various cumulative atropine doses showed progression in low-refractive-error eyes, although these were significantly less than those of the untreated group (Table 3). As for high-refractive-error eyes, the mean SE of all atropine-treated groups showed a refractive error regression, in contrast with the myopic progression in the untreated group (Table 4). The mean IOP of all atropine-treated groups showed no significant increase in either low- or high-refractive-error eyes (Tables 3 and 4). The effect of slowing the progression of myopia caused almost no significant differences between the low- and high-cumulative atropine dosage subgroups, except that the subgroup of left eyes with low refraactive error and low-cumulative atropine dosage displayed significantly lower myopia progression than the subgroup of high-cumulative atropine dosage (Table 3).

### 4. Discussion

Myopia is not only an ocular disease but also a serious public health problem, affecting 33% of individuals over the age of 12 years in the United States[14] and a much higher percentage (60%–80%) in Southeast Asian countries such as Taiwan and Singapore.[12, 14] The prevalence of myopia and severe myopia are increasing at an alarming rate globally, with significant increases in the risks for visual impairment from pathologic conditions related

| Characteristics  | Control group | Low-dose atropine group (cumulative dose < 40) | High-dose atropine group (cumulative dose ≥ 40) |
|------------------|---------------|-----------------------------------------------|-----------------------------------------------|
| Number of eyes   | 40            | 33                                            | 25                                            |
| Age (year)       | 9.44±2.45     | 8.18±1.68*                                    | 8.26±1.83                                     |
| Male/female      | 22/18         | 13/20                                         | 14/11                                         |
| Cumulative dose of atropine (mg) | 0.00±0.00 | 26.06±7.55*                                   | 68.00±41.33*                                  |
| Initial SE (D)   | −0.70±0.45    | −0.79±0.44                                    | −0.97±0.32                                    |
| IOP (mm Hg)      | 14.68±2.94    | 13.46±3.00                                    | 13.16±2.04                                    |
| Final SE (D)     | −2.00±1.41    | −1.01±0.61                                    | −1.42±0.72                                    |
| IOP (mm Hg)      | 15.78±2.52    | 13.97±2.80                                    | 14.24±2.71                                    |
| Mean difference  | −1.30±1.35    | −0.22±0.68*                                   | −0.45±0.71*                                   |

D = diopter, IOP = intraocular pressure, OD = oculus dexter, OS = oculus sinister, SE = spherical equivalent.

Data are means ± standard deviation. *P < .05 compared to the control group. **P < .05 compared between the two atropine-treated groups.
Table 4
Comparison of demographic and clinical characteristics between various cumulative atropine dosages in eyes with −1.5 Diopter or greater of myopic spherical equivalent (SE ≤ −1.5D).

| Eye laterality | Control group (cumulative dose = 0) | Low-dose atropine group (cumulative dose < 40) | High-dose atropine group (cumulative dose ≥ 40) |
|---------------|------------------------------------|-----------------------------------------------|-----------------------------------------------|
|               | 25 9.83±2.02 0.00±0.00 0.00±0.00 | 27 9.10±3.13 2.53±1.43 2.43±1.71 | 36 8.98±2.37 2.84±1.84 2.74±1.71 |
|               | 15/9 16/9 0.00±0.00 | 12/15 0.00±0.00 | 21/15 0.00±0.00 |
|               | 9.14±2.18 15.76±3.18 1.00±0.91 | 14.16±1.84 15.44±2.41 0.11±0.15 | 14.64±2.37 15.08±2.54 0.44±3.29 |
|               | 1.60±2.97 1.49±1.71 1.51±1.49 | 1.45±1.45 1.51±1.45 1.49±1.71 | 2.03±8.91 1.84±1.84 2.26±1.71 |
| Number of eyes | 25 | 27 | 36 |
| Age (year) | 9.83±2.02 | 9.10±3.13 | 8.98±2.37 |
| Male/female | 16/9 | 12/15 | 21/15 |
| Cumulative dose of atropine (mg) | 0.00±0.00 | 0.00±0.00 | 0.00±0.00 |
| Initial SE (D) | 2.93±1.89 | 2.53±1.43 | 2.84±1.84 |
| IOP (mm Hg) | 14.16±1.84 | 15.76±3.18 | 14.64±2.37 |
| Final SE (D) | −4.23±2.59 | −2.43±1.71 | −2.74±1.71 |
| IOP (mm Hg) | 15.44±2.41 | 15.08±3.19 | 15.00±2.63 |
| Mean difference | −1.30±1.65 | 0.11±0.91 | 0.10±1.58 |
| IOP (mm Hg) | 1.60±2.97 | 1.49±1.71 | 2.03±8.91 |

**D** = diopter, **IOP** = intraocular pressure, **OD** = occultus dexter, **OS** = occultus sinister, **SE** = spherical equivalent.

Data are mean ± standard deviation. *P* < .05 compared with control group. **P** < .05 compared between atropine-treated groups.

Table 4 shows the comparison of demographic and clinical characteristics between various cumulative atropine dosages in eyes with −1.5 Diopter or greater of myopic spherical equivalent (SE ≤ −1.5D). The table includes the number of eyes, age, sex, cumulative dose of atropine, initial and final spherical equivalent (SE), and intraocular pressure (IOP) in different groups. The results indicate that there is no significant difference in the mean SE between the subgroup of the highest cumulative atropine dose and the untreated group, although previous studies suggested that a higher concentration of atropine use results in better myopia control.[11,13,17,20] The probable explanations for this discrepancy are the different study design used in our research, the limited number of cases covered, and the relatively shorter follow-up period. This study focused on the effect of cumulative atropine dose, which was affected by the atropine concentration and the duration of therapy. A high cumulative dose might not necessarily mean a high concentration of the drug was administered at each treatment, and this difference in our study design might cause conflicting results.

The final IOP results revealed an inconsistency in our study. There was no significant difference between the atropine-treated group and the untreated group at recruitment, but different results were found between patients’ left and right eyes after 1 year. With regard to the left eyes, there was no significant IOP difference between two groups, but in the right eyes the mean IOPs of all atropine-treated subgroups stratified by tertiles of cumulative dose were lower than those in the untreated group (P=.048). This inconsistency in our IOP results might be the result of the method of IOP measurements used. The Goldmann applanation tonometer is thought to be the gold standard for measuring IOP, but the non-contact tonometer is clinically more tolerable for children.[13] We, therefore, used the pneumotonometer for IOP measurement in this study. Sihota et al suggested that the success rate of measuring IOP was 95% in children aged ~6 years and was near 100% in those older than 7 years.[13] The myopic children included in this study were aged between 3 and 17 years, and the mean age of all children was 9.2 years old. If there is a bias in IOP measurements, it should be relatively low.[13,35] Our study showed the mean IOP was not correlated with the cumulative atropine dose and did not increase in all atropine-treated subgroups of various cumulative dose.

Previous studies suggested that IOP is lower in children than in adults[34,36–41] and showed an increasing trend with age (correlation coefficient = 0.49–0.71), reaching adult levels by 12 years of age.[34,36,39] Therefore, IOP evaluation in children should take physiologic age levels as a reference. In our study, the revealed no significant difference of mean SE between the subgroup of the highest cumulative atropine dose and the untreated group, although previous studies suggested that a higher concentration of atropine use results in better myopia control.[11,13,17,20] The probable explanations for this discrepancy are the different study design used in our research, the limited number of cases covered, and the relatively shorter follow-up period. This study focused on the effect of cumulative atropine dose, which was affected by the atropine concentration and the duration of therapy. A high cumulative dose might not necessarily mean a high concentration of the drug was administered at each treatment, and this difference in our study design might cause conflicting results.

The final IOP results revealed an inconsistency in our study. There was no significant difference between the atropine-treated group and the untreated group at recruitment, but different results were found between patients’ left and right eyes after 1 year. With regard to the left eyes, there was no significant IOP difference between two groups, but in the right eyes the mean IOPs of all atropine-treated subgroups stratified by tertiles of cumulative dose were lower than those in the untreated group (P=.048). This inconsistency in our IOP results might be the result of the method of IOP measurements used. The Goldmann applanation tonometer is thought to be the gold standard for measuring IOP, but the non-contact tonometer is clinically more tolerable for children.[13] We, therefore, used the pneumotonometer for IOP measurement in this study. Sihota et al suggested that the success rate of measuring IOP was 95% in children aged ~6 years and was near 100% in those older than 7 years.[13] The myopic children included in this study were aged between 3 and 17 years, and the mean age of all children was 9.2 years old. If there is a bias in IOP measurements, it should be relatively low.[13,35] Our study showed the mean IOP was not correlated with the cumulative atropine dose and did not increase in all atropine-treated subgroups of various cumulative dose.

Previous studies suggested that IOP is lower in children than in adults[34,36–41] and showed an increasing trend with age (correlation coefficient = 0.49–0.71), reaching adult levels by 12 years of age.[34,36,39] Therefore, IOP evaluation in children should take physiologic age levels as a reference. In our study, the

to severe myopia, including macular degeneration, retinal detachment, cataracts, and glaucoma.[14,6–9] The high prevalence of myopia and associated vision-threatening problems emphasize the importance of finding effective treatments to slow the progression of myopia and axial elongation. Atropine is the most studied pharmacological agent for the topical treatment of progressive myopia[10–17] and has become a main strategy for slowing the progression of myopia throughout East and Southeast Asia.[15,17–20] As a non-selective muscarinic antagonist, atropine causes pupil dilation and may predispose sufferers to glaucoma.[22,33] Besides, previous large population-based studies had supported an association between glaucoma and myopia. Myopic subjects had a 2 to 14 times higher risk of glaucoma compared with that of non-myopic subjects.[24–29] However, it is unclear whether topical atropine therapy causes further development of glaucoma in myopic children.[21,22] We, therefore, conducted a retrospective study in 2012 and found that neither the cumulative dose nor the duration of atropine therapy caused significant IOP elevation.[23] Another prospective study also suggested that topical use of low-concentration atropine for 1 year did not induce ocular hypertension.[40] After considering whether various cumulative dosages of atropine led to different results, we decided to conduct this study to gather a more complete picture of the issue.

In our study, the mean age of the atropine-treated group was significantly younger than the untreated group (P < .001). We assume that this result may be due to previous atropine treatment at a younger age in the myopic patients we treated. Previous randomized control trials have suggested that children who develop myopia at a younger age experience a faster progression of the condition.[11,22] In order to avoid irreversible myopic change and complications, timely atropine treatment may be beneficial. Our results showed significantly lesser myopic progression in the atropine-treated group than the untreated group at the end of their 1-year follow-up (P < .01), whether in spherical power, cylinder power, or SE. The outcome was comparable to those of previous studies that found that atropine treatment may prevent the progression of myopia.[10–13,15–20]

Subgroup analysis by tertiles of cumulative atropine dose showed that the effect of slowing the progression of myopia was irrelevant to the cumulative atropine dose. The post hoc analysis revealed no significant difference of mean SE between the subgroup of the highest cumulative atropine dose and the untreated group, although previous studies suggested that a higher concentration of atropine use results in better myopia control.[11,13,17,20] The probable explanations for this discrepancy are the different study design used in our research, the limited number of cases covered, and the relatively shorter follow-up period. This study focused on the effect of cumulative atropine dose, which was affected by the atropine concentration and the duration of therapy. A high cumulative dose might not necessarily mean a high concentration of the drug was administered at each treatment, and this difference in our study design might cause conflicting results.
mean age of the atropine-treated group was 8.6 years and the normal pediatric IOP cutoff level was estimated to be ~16 mm Hg. Although there was no significant increase in the final mean IOP after 1 year of atropine therapy, we should keep in mind that the mean value cannot be representative of the total population. Out of 242 eyes receiving atropine therapy, 74 eyes (30.6%) had final IOPs of more than 16 mm Hg, but further exams such as optical coherence tomography (OCT) and visual field tests were still needed to determine whether any related glaucomatous change had occurred. Chan et al performed OCT on 67 eyes of 35 myopic children receiving 0.25% atropine treatment, and found no significant change in IOP, optic nerve parameters, or retinal nerve fiber layer thickness over a mean of 15.2 ± 2.4 months of treatment and follow-up.

In our study, the mean differences of IOPs in the atropine-treated groups were all lower than the untreated group, although these findings were not statistically significant. However, the observed IOP increases were significantly higher in the atropine-treated group than in the control group. This finding is consistent with previous studies that have shown a modification of IOP in children with myopia treated with atropine. Nevertheless, further studies with a larger sample size and longer follow-up period and a larger sample size are still needed to determine whether any related glaucomatous change had occurred. Chan et al performed OCT on 67 eyes of 35 myopic children receiving 0.25% atropine treatment, and found no significant change in IOP, optic nerve parameters, or retinal nerve fiber layer thickness over a mean of 15.2 ± 2.4 months of treatment and follow-up.

There are some limitations in this study. First, it is not a double-blind randomized design, and second it used a relatively small sample size and short follow-up period. Third, we used a non-contact pneumotonometer to evaluate IOP with only single measurement. The Goldmann applanation tonometer is considered the gold standard for measuring IOP, but the non-contact tonometer is clinically more tolerable for children. We, therefore, used the latter method for measuring IOP in this study. Jaafar and Kaz reported that the IOP measurements obtained using a pneumotonometer significantly higher than those obtained compared with the Perkins tonometer, which uses the same principle as the Goldmann tonometer. Therefore, it is possible that the prevalence of high IOP may be underestimated, especially in younger children. Repeated measurements of IOP may be performed to reduce potential bias. Furthermore, we did not have any data on corneal thickness that might be associated with IOP, nor on exam results other than IOP to diagnose glaucoma, such as gonioscopy, OCT, or visual field. As for detecting myopic progression, we did not measure axial length elongation for a more comprehensive evaluation.

To the best of our knowledge, this is the first prospective study to evaluate the effects of varying cumulative atropine dosages and shows no physiologically high IOPs in myopic children following the application of atropine for one year. Similar to other studies, topical atropine eye drops are effective in slowing the progression of myopia. However, the treatment effects are not correlated with cumulative atropine dosages. Further studies with a longer follow-up period and a larger sample size are still needed to confirm our results.

Author contributions
Investigation: Teng-Chieh Yu, Tzu-En Wu.
Supervision: Tzu-En Wu, Shiw-Wen Liou.
Writing – original draft: Teng-Chieh Yu, Tzu-En Wu.
Writing – review & editing: Yuan-Shen Wang, Shen-Fu Cheng, Tzu-En Wu.

References
[1] Group TFOESF. Familial aggregation and prevalence of myopia in the Framingham Offspring Eye Study. Arch Ophthalmol 1996;114:326–32.
[2] Lin LL, Shih YF, Tsai CB, et al. Epidemiologic study of ocular refraction among schoolchildren in Taiwan in 1995. Optom Vis Sci 1999;76:275–81.
[3] Saw SM, Katz J, Schein OD, et al. Epidemiology of myopia. Epidemiol Rev 1996;18:175–87.
[4] Tan NW, Saw SM, Lam DS, et al. Temporal variations in myopia progression in Singaporean children within an academic year. Optom Vis Sci 2000;77:465–72.
[5] Vitale S, Elwein L, Cotch MF, et al. Prevalence of refractive error in the United States, 1999–2004. Arch Ophthalmol 2008;126:1111–9.
[6] Fan DS, Lam DS, Lam RF, et al. Prevalence, incidence, and progression of myopia of school children in Hong Kong. Invest Ophthalmol Vis Sci 2004;45:1071–5.
[7] Mitchell P, Houihan F, Sandbach J, et al. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology 1999;106:2010–5.
[8] Pierro I, Camesasca F, Mischi M, et al. Peripheral retinal changes and axial myopia. Retina (Philadelphia, Pa) 1992;12:12–7.
[9] Dandonia R, Dandonia L. Refractive error blindness. Bull World Health Organ 2001;79:237–43.
[10] Chou AC, Shih YF, Ho TC, et al. The effectiveness of 0.5% atropine in controlling high myopia in children. J Ocul Pharmacol Ther 1997;13:61–7.
[11] Fan DS, Lam DS, Chan CK, et al. Topical atropine in retarding myopic progression and axial length growth in children with moderate to severe myopia: a pilot study. Jpn J Ophthalmol 2007;51:27–33.
[12] Lee JJ, Fang PC, Yang IH, et al. Prevention of myopia progression with 0.05% atropine solution. J Ocul Pharmacol Ther 2006;22:41–6.
[13] Shih YF, Chen CH, Chou AC, et al. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther 1999;15:85–90.
[14] Shih YF, Hsiao CK, Chen CJ, et al. An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression. Acta Ophthalmol Scand 2001;79:233–6.
[15] Tong L, Huang XL, Koh AL, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology 2009;116:572–9.
[16] Yen MY, Liu JH, Kao SC, et al. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol 1989;21:180–2. 187.
[17] Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006;113:2285–91.
[18] Fang YT, Chou YJ, Pu C, et al. Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study. Eye (London, England) 2013;27:418–24.
[19] Saw SM, Gazzard G, Au Eong KG, et al. Myopia: attempts to arrest progression. Br J Ophthalmol 2002;86:1306–11.
[20] Song YY, Wang H, Wang BS, et al. Atropine in ameliorating the progression of myopia in children with mild to moderate myopia: a meta-analysis of controlled clinical trials. J Ocul Pharmacol Ther 2011;27:361–8.
[21] Greenstein SH, Abramson DH, Pitts WR3rd. Systemic atropine and glaucoma. Bull NY Acad Med 1984;60:961–8.
[22] Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Can J Ophthalmol 2007;42:129–33.
[23] Wu TE, Yang CC, Chen HS. Does atropine use increase intraocular pressure in myopic children? Optom Vis Sci 2012;89:E161–7.
[24] Czudowska MA, Ramdas WD, Wolfs RC, et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. Ophthalmology 2010;117:1705–12.
[25] Ramakrishnan R, Nirmalan PK, Krishnadas R, et al. Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey. Ophthalmology 2003;110:1484–90.
[26] Suzuki Y, Iwase A, Arase M, et al. Risk factors for open-angle glaucoma in a Japanese population: the Tajimi Study. Ophthalmology 2006;113:1613–7.
[27] Varma R, Wang D, Wu C, et al. Four-year incidence of open-angle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study. Am J Ophthalmol 2012;154:315–25.e311.
[28] Xu L, Wang Y, Wang S, et al. High myopia and glaucoma susceptibility: the Beijing Eye Study. Ophthalmology 2007;114:216–20.
[29] Wong TY, Klein BE, Klein R, et al. Refractive errors, intraocular pressure, and glaucoma in a white population. Ophthalmology 2003;110:211–7.
[30] Lee CY, Sun CC, Lin YF, et al. Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study. BMC Ophthalmol 2016;16:114.
[31] Hyman L, Gwiazda J, Hussein M, et al. Relationship of age, sex, and ethnicity with myopia progression and axial elongation in the correction of myopia evaluation trial. Arch Ophthalmol 2005;123:977–87.
[32] Saw SM, Nieto FJ, Katz J, et al. Factors related to the progression of myopia in Singaporean children. Optom Vis Sci 2000;77:549–54.
[33] Brencher HL, Kohl P, Renke AR, et al. Clinical comparison of air-puff and Goldmann tonometers. J Am Optom Assoc 1991;62:395–402.
[34] Sihota R, Tuli D, Dada T, et al. Distribution and determinants of intraocular pressure in a normal pediatric population. J Pediatr Ophthalmol Strabismus 2006;43:14–8. quiz 36–17.
[35] Moreno-Montañés J, Gómez-Demmel E, Lajara-Blesa J, et al. Comparative study of three non-contact Tonometers and the Goldmann Tonometer. Ophthalmologica 1994;208:115–8.
[36] Bresson-Dumont H. Intraocular pressure measurement in children. J français d'ophtalmologie 2009;32:176–81.
[37] Edwards MH, Brown B. Intraocular pressure in a selected sample of myopic and nonmyopic Chinese children. Optom Vis Sci 1993;70:15–7.
[38] Edwards MH, Chun CY, Leung SS. Intraocular pressure in an unselected sample of 6- to 7-year-old Chinese children. Optom Vis Sci 1993;70:198–200.
[39] Jaafar MS, Kazi GA. Normal intraocular pressure in children: a comparative study of the Perkins applanation tonometer and the pneumotonometer. J Pediatr Ophthalmol Strabismus 1993;30:284–7.
[40] Jiang WJ, Wu JF, Hu YY, et al. Intraocular pressure and associated factors in children: the Shandong children eye study. Invest Ophthalmol Vis Sci 2014;55:4128–34.
[41] Pensiero S, Da Pozzo S, Perissutti P, et al. Normal intraocular pressure in children. J Pediatr Ophthalmol Strabismus 1992;29:79–84.
[42] Chan LW, Hsieh YT, Hsu WC, et al. Optic disc parameters of myopic children with atropine treatment. Curr Eye Res 2017;42:1614–9.
[43] Herring JP, Pickett JP, Champagne ES, et al. Effect of topical 1% atropine sulfate on intraocular pressure in normal horses. Vet Ophthalmol 2000;3:139–43.
[44] Mughannam AJ, Buyukmihci NC, Kass PH. Effect of topical atropine on intraocular pressure and pupil diameter in the normal horse eye. Vet Ophthalmol 1999;2:213–5.
[45] Stadtbaumer K, Frommlet F, Nell B. Effects of mydriatics on intraocular pressure and pupil size in the normal feline eye. Vet Ophthalmol 2006;9:233–7.
[46] Harris LS. Cycloplegic-induced intraocular pressure elevations a study of normal and open-angle glaucomatous eyes. Arch Ophthalmol 1968;79:242–6.
[47] Hadijkoutis S, Morgan JE, Wild JM, et al. Ocular complications of neurological therapy. Eur J Neurol 2005;12:499–507.